Cited 6 times in
From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.date.accessioned | 2017-10-26T07:55:19Z | - |
dc.date.available | 2017-10-26T07:55:19Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2162-4011 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152696 | - |
dc.description.abstract | Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer-targeted microRNA drug, MRX34. Yet, these microRNAs are mostly being studied and clinically trialed solely based on the understanding of their cell biologic effects, thus, neglecting the important immunologic effects that are sometimes opposite of the cell biologic effects. Here, we summarize both the cell biologic and immunologic effects of various microRNAs and discuss the importance of considering both effects before using them in clinical settings. We stress the importance of understanding the miRNA's effect on cancer metastasis from a "systems" perspective before developing a miRNA-targeted therapeutic in treating cancer metastasis. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Taylor & Francis | - |
dc.relation.isPartOf | ONCOIMMUNOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pediatrics | - |
dc.contributor.googleauthor | Jae Hyon Park | - |
dc.contributor.googleauthor | Evropi Theodoratou | - |
dc.contributor.googleauthor | George A. Calin | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.identifier.doi | 10.1080/2162402X.2016.1230579 | - |
dc.contributor.localId | A02142 | - |
dc.relation.journalcode | J03037 | - |
dc.identifier.eissn | 2162-402X | - |
dc.relation.journalsince | 2012 | - |
dc.identifier.pmid | 27999740 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139645/ | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | Shin, Jae Il | - |
dc.citation.volume | 5 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1230579 | - |
dc.identifier.bibliographicCitation | ONCOIMMUNOLOGY, Vol.5(11) : 1230579, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 39705 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.